In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endo gets N. American rights to Vernalis's Frova

Executive Summary

Endo Pharmaceuticals (pain management) has been granted exclusive North American rights to Vernalis PLC's (focused on neurology and oncology) Frova (frovatriptan), which is approved for acute treatment of migraine headaches with or without aura in adults.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies